Lisaftoclax (APG-2575) is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy.
Jing DengAneel PaulusDouglas D FangAlak MannaGuangfeng WangHengbang WangSaijie ZhuJianyong ChenPing MinYan YinNavnita DuttaNabanita HalderGina CiccioJohn A Copland IiiJames L MillerBing HanLongchuan BaiLiu LiuMi WangDonna McEachernSally PrzybranowskiChao-Yie YangJeanne A StuckeyDe-Pei WuCaixia LiJeremy Adam RyanAnthony G LetaiSikandar AilawadhiDajun YangShaomeng WangAsher A Chanan-KhanYifan ZhaiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
These findings demonstrate that lisaftoclax is a novel, orally bioavailable BH3 mimetic BCL-2-selective inhibitor with considerable potential for the treatment of certain hematologic malignancies.